The new inhaler replaces Trixeo Aerosphere’s existing gas propellant with a low global warming-potential alternative.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Patients with COPD and chronic hypercapnic respiratory failure on noninvasive ventilation report similar quality of life ...

Across four prospective U.S. cohorts, 4.5% of those 18-49 years old met criteria for COPD, defined as spirometric airflow ...

As extreme heat settles over Illinois, the American Lung Association has tips to help residents safeguard their health. Extreme weather conditions, like the current heat wave, can be especially ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

Urine VOCs are linked to COPD risk and inflammation in NHANES data, suggesting potential for non-invasive screening with ...

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksTh ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

Residents including parents of children who have received care for two conditions — asthma and chronic obstructive pulmonary disease — have been asked to assist in guiding the island’s healthcare ...